Ibsrela Tablet
Product Images NDC 73154-050

Product Visual Gallery

This gallery contains 4 technical images submitted to the FDA as part of the official labeling for Ibsrela (NDC 73154-050). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by Ardelyx, Inc., these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

FDA Label Image

Image (Ibsrela 01)

FDA Label Image

Chemical Structure (Ibsrela 02)

FDA Label Image

Principal Display Panel (50 mg Tablet Bottle Label)

This is a medication, indicated for adults with chronic idiopathic constipation (CIC) and irritable bowel syndrome with constipation (IBS-C) conditions. The medicine comes in the form of tablets, with each containing 53.2 mg tenapanor hydrochloride. The tablets should be stored between 15°C and 30°C (59°F and 86°F). The recommended dosing is one tablet twice daily. The medication should be dispensed with the accompanying medication guide to each patient. This medicine should be kept out of the reach of children. For more information, please see the full prescribing information.*

FDA Label Image

Ibsrela 04

This is a professional sample of IBSRELA tablets, containing 6 tablets with 53.2 mg of tenapanor hydrochloride in each tablet. It is meant for dispensing by a pharmacist with accompanying medication guide to be given to each patient. The tablets should not be removed from the original container and should be stored at 26°C with excursions permitted between 15°C and 30°C. The recommended dose is one tablet twice daily. Full prescribing information is available. Ardelyx, Inc. distributes these tablets in Waltham, MA. Lot number and expiration date are also provided.*

* These product label images have been analyzed using experimental machine learning. Please verify findings with the primary label text.